Holy Grail develops energy storage and battery technology that uses electrons to capture carbon dioxide from the atmosphere. It leverages AI and is involved in the research, development, and engineering of various products like batteries, catalysts, and materials datasets which can be used to cross-validate predictions and simulations of experimental data, enabling industrial clients to ensure and benefit from energy efficiency and economy.
To help hospitals reduce preventable errors and cut down costs in litigation, Scalpel Ltd. is building an end to end patient safety platform. This AI-powered platform checks and verifies the implementation of safety steps during surgery using a combination of computer vision and machine learning technologies. Unlike standard checklists, Scalpel’s solution doesn’t require any human interaction. Sitting in the background in an operating room it automatically monitors the process and provides real-time feedback to detect and prevent errors.
Thermulon has developed the first building insulation material to satisfy the criteria of fire-safety, performance and price. Designed from the molecular level up, Thermulon deploys the latest advances in chemical and processing technology into an insulation product that enables buildings to be energy efficient without compromising on fire safety.
Ancilia develops novel bacterial therapies that target the viral components of the microbiome to address chronic diseases across immunology and oncology indications. Our approach harnesses the natural function of CRISPR to enhance bacterial immunity against viruses and effectively modulate the human microbiome.
Supercritical Solutions is on a mission to eliminate the hardest 20% of global emissions, with technology to slash the cost of green hydrogen for the world’s biggest emitters this decade. Its technology can transform global industries and enable a world beyond fossil fuels.
The Engineering Company aims to trigger the next industrial revolution by building technology that radically accelerates the invention process. The platform allows enables the design industrial hardware on a profoundly deeper complex level in a tenth of the speed. The company intends their platform to power the next 100 years of hardware invention.
Concr combines cutting edge machine learning techniques with a deep scientific understanding of tumour progression to accurately predict cancer evolution in response to treatment. This will enable clinicians to adapt treatments proactively, rather than reactively, to prevent treatment resistance and improve treatment efficacy through precision medicine. Concr aims to: • Reduce treatment resistance • Cut the cost of cancer treatment • Enable proactive treatment adaptation • Save lives